Screening for Depression in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement

Area of Science:

• Preventive medicine
• Child and adolescent psychiatry
• Public health guidelines

Background:

• The U.S. Preventive Services Task Force (USPSTF) previously issued recommendations on major depressive disorder (MDD) screening in 2009.
• This update reviews current evidence on screening, diagnosis, and treatment for pediatric populations.

Purpose of the Study:

• To provide an updated recommendation on screening for major depressive disorder (MDD) in children and adolescents.
• To evaluate the benefits and harms of screening and subsequent treatment modalities.

Main Methods:

• Systematic review of evidence on screening accuracy, benefits, and harms of treatment (psychotherapy, medications, collaborative care).
• Focused on patients aged 7 to 18 years without a prior MDD diagnosis.
• Incorporated data from studies published since the 2009 guideline.

Main Results:

• Recommends screening for MDD in adolescents aged 12 to 18 years (B recommendation).
• Current evidence is insufficient to assess screening benefits and harms in children aged 11 years or younger (I statement).
• Emphasizes the need for accurate diagnosis, effective treatment, and follow-up systems.

Conclusions:

• Screening for major depressive disorder is recommended for adolescents aged 12-18.
• Implementation requires adequate systems for diagnosis, treatment, and follow-up.
• Insufficient evidence exists for screening younger children (≤11 years).